Tick Insights

Search Icon

Menu Toggle Icon

Skip to content
  • Home
  • Forex
  • CFD Indices
  • CFD Equities
  • Education
  • Events
Tick Insights

Tag: Fosun Pharma

CFD Trading – Buy Fosun Pharma (2196.HKE) at $43.75. Stop at $36.70 and Target at $52.40.

April 5, 2022April 5, 2022Shueh Ting Wong

FOSUN PHARMA   Stock Code 2196.HKE

Outlook

Price broke and closed above its recent price high, suggesting the bullish momentum of the stock price.… Read More

CFD Equities CFD HK Trading Note, Fosun Pharma Leave a comment

CFD Trading – Buy Fosun Pharma (2196.HKE) at $40.50. Stop at $39.00 and Target at $48.20

March 22, 2022March 22, 2022Shueh Ting Wong

FOSUN PHARMA   Stock Code 2196.HKE

Outlook

Price broke and closed above the cloud, changing the chart outlook from bearish to bullish.… Read More

CFD Equities CFD HK Trading Note, Fosun Pharma Leave a comment

CFD Trading – Buy Fosun Pharma (2196.HKE) at $70.70. Stop at $64.40 and Target at $80.60

July 22, 2021Shueh Ting Wong
FOSUN PHARMA   Stock Code 2196.HKE

Outlook

Price broke out from a Triangle pattern on 16 July and it has been advancing higher since then.… Read More

CFD Equities CFD HK Trading Note, Fosun Pharma Leave a comment

About Us

Tick Insights

UTRADE

Upcoming Webinar

US & HK ETF Available For CFD Trade

Stay Connected

Subscribe to this blog and receive notifications of new posts by email.

Like our Facebook page for the latest updates!

 SG UTRADE

Recent Posts

  • FX Commentary – US Dollar Rose, Aided By Safe Haven Demand
  • CFD Trading – Buy Ascendas Reit (A17U.SGX) @ $2.87. Stop @ $2.81 and Target @ $2.96.
  • CFD Trading – Buy Jardine C&C (C07.SGX) @ $28.00. Stop @ $26.00 and Target @ $32.00.
  • FX Commentary – US Dollar Slipped On Treasury Yields Decline.
  • CFD Indices – Wall Street Stumbled On Poor Consumer Confidence

Archives

Disclaimer

This information is prepared by personnel in UOB Kay Hian’s Alternative Products Department and is not the product of UOB Kay Hian’s Research Department. It is not a research report and is not intended as such, although a UOB Kay Hian Research report may be referenced as a link or as an attachment hereto.

Opinions expressed herein may differ from the opinions expressed by other areas of UOB Kay Hian, including research. This commentary is provided for information only. Neither the information nor any views expressed constitutes a solicitation for the purchase or sale of any securities or other financial instruments. It is not a personal recommendation, offer or solicitation to buy or sell.

Scroll to Top
 

Loading Comments...